专利检索 ap:("DUQUESNE UNIVERSITY OF THE HOLY GHOST" OR "WAYNE STATE UNIVERSITY") AND inv:"LARRY H. MATHERLY" 第 1 页

1.

发明申请
SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES FOR SELECTIVELY TARGETING TUMOR CELLS WITH FR-ALPHA AND FR-BETA TYPE RECEPTORS 审中-公开
标题翻译：用于选择性靶向具有FR-ALPHA和FR-型受体的肿瘤细胞的替代吡咯并[2,3-D]吡啶

公开(公告)号：US20170015672A1

公开(公告)日：2017-01-19

申请号：US15280724

申请日：2016-09-29

申请人： DUQUESNE UNIVERSITY OF THE HOLY GHOST , WAYNE STATE UNIVERSITY

发明人： ALEEM GANGJEE , LARRY H. MATHERLY

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： Pyrrolo[2,3-d]pyrimidine derivatives, and pharmaceutical acceptable salts thereof, useful in therapeutically treating patients with cancer are disclosed. These compounds selectively target folate receptors (FR) of cancerous tumor cells and inhibit purine synthesis and hence, DNA synthesis.

摘要翻译： 公开了可用于治疗癌症患者的吡咯并[2,3-d]嘧啶衍生物及其药学上可接受的盐。这些化合物选择性靶向癌性肿瘤细胞的叶酸受体（FR），并抑制嘌呤合成，从而抑制DNA合成。

2.

发明申请
SUBSTITUTED PYRROLO[2,3-D]DIPYRIMIDINES FOR SELECTIVELY TARGETING TUMOR CELLS WITH FR-ALPHA AND FR-BETA TYPE RECEPTORS 有权
标题翻译：用于选择性靶向具有FR-ALPHA和FR-型受体的肿瘤细胞的替代吡咯并[2,3-D]二嘧啶

公开(公告)号：US20160229857A1

公开(公告)日：2016-08-11

申请号：US14617332

申请日：2015-02-09

申请人： Duquesne University of The Holy Ghost

发明人： ALEEM GANGJEE , LARRY H. MATHERLY

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： Pyrrolo[2,3-d]pyrimidine derivatives, and pharmaceutical acceptable salts thereof, useful in therapeutically treating patients with cancer are disclosed. These compounds selectively target folate receptors (FR) of cancerous tumor cells and inhibit purine synthesis and hence, DNA synthesis.

摘要翻译： 公开了可用于治疗癌症患者的吡咯并[2,3-d]嘧啶衍生物及其药学上可接受的盐。这些化合物选择性靶向癌性肿瘤细胞的叶酸受体（FR），并抑制嘌呤合成，从而抑制DNA合成。

3.

发明申请
SELECTIVE PROTON COUPLED FOLATE TRANSPORTER AND FOLATE RECEPTOR, AND GARFTASE INHIBITOR COMPOUNDS AND METHODS OF USING THE SAME 审中-公开

公开(公告)号：US20180346474A1

公开(公告)日：2018-12-06

申请号：US16000954

申请日：2018-06-06

申请人： Duquesne University of the Holy Spirit , WAYNE STATE UNIVERSITY

发明人： Aleem Gangjee , LARRY H. MATHERLY

IPC分类号： C07D487/04 , A61K31/519

CPC分类号： C07D487/04 , A61K31/519

摘要： Fused cyclic pyrimidine compounds, including tautomers thereof, and pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, are disclosed having the general Formula I: These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and/or folate receptor beta pathways, inhibiting GARFTase in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such as rheumatoid arthritis.